Announcement PDF Company Announcement IMAGION BIOSYSTEMS LIMITED ASX: IBX 28 June 2023 Imagion expands collaboration with Siemens Healthineers to United States MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detecƟon of cancer, is pleased to announce it has expanded its collaboraƟon agreement with Siemens Healthineers. In addiƟon to extending the exisƟng agreement with Siemens Healthcare Pty Ltd of Australia for an addiƟonal two years, the companies have agreed to collaborate in the United States through Siemens Medical SoluƟons USA. This U.S. extension is in anƟcipaƟon of Imagion’s undertaking a mulƟ-site Phase 2 study for the MagSense® HER2 imaging agent. Through the collaboraƟon, Siemens Healthineers will make an inkind contribuƟon of experƟse working with Imagion and Imagion’s clinical advisors and invesƟgators to opƟmize the MagneƟc Resonance Imaging (MRI) protocols in anƟcipaƟon of Imagion’s MagSense® clinical studies, and provide limited technical support to clinical sites. The collaboraƟon in the MagSense® Phase 1 study in Australia has been very valuable and is expected to conƟnue now in this expanded capacity in the United States. “We have been very pleased with and appreciaƟve of the collaboraƟon with Siemens Healthineers in our Phase 1 study in Australia,” said Bob Proulx, ExecuƟve Chairman of Imagion Biosystems. “The company was instrumental in the early stages to help establish the iniƟal MRI protocols that were implemented in our study, and has contributed to ongoing evaluaƟon and opƟmizaƟon to achieve the best data possible for our MagSense® imaging agent in breast cancer paƟent lymph nodes. This collaboraƟon creates a win-win situaƟon in which Imagion benefits from having access to the Siemens Healthineers MRI research team’s knowledge and experƟse, while providing Siemens Healthineers direct visibility to our work to make molecular MRI a reality.” To date, MRI contrast agents have been general-purpose, improving image resoluƟon by creaƟng contrast at Ɵssue boundaries or within Ɵssue but not providing funcƟonal imaging uƟlity. Imagion’s MagSense® imaging agents could enable a first-of-its-kind molecular imaging soluƟon for MRI. By changing current pracƟce in medical imaging to include the sensiƟve and selecƟve detecƟon of cancer cells without using radiaƟon, Imagion’s technology could significantly improve cancer diagnosis and paƟent care. Imagion Biosystems presented its first clinical data for the MagSense® HER2 imaging agent in December 2022 at the San Antonio Breast Cancer Symposium. Since then, the company has reported findings from an independent review and its intenƟon to proceed with filing an InvesƟgaƟonal New Drug (IND) applicaƟon with the U.S. Food and Drug AdministraƟon to undertake a mulƟ-site Phase 2 study. This collaboraƟon will support the future studies.  ENDS  About Imagion Biosystems Imagion Biosystems is developing a new non-radioacƟve and precision diagnosƟc molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. For more informaƟon, visit hƩps://imagionbiosystems.com/investor-hub/ Imagion Biosystems InteracƟve Investor Hub Engage with us directly by asking quesƟons, watching video summaries, and seeing what other shareholders have to say about this and past announcements at our Investor Hub: hƩps://investorhub.imagionbiosystems.com/ AuthorisaƟon & AddiƟonal informaƟon This announcement was authorised by the Disclosure CommiƩee of Imagion Biosystems Limited Australian Media & Investor RelaƟons: Hannah HowleƩ, WE CommunicaƟons We-AUImagionBiosystems@we-worldwide.com +61 450 648 064 U.S. Media Contact Casie Ost casie.ost@imagionbio.com +1-619-693-4428